Premium
Analysis of clinical characteristics of tigecycline‐induced acute pancreatitis
Author(s) -
Fang Weijin,
Yi Dan,
Sun Linli,
Wang Chunjiang
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13212
Subject(s) - medicine , acute pancreatitis , pancreatitis , tigecycline , nausea , vomiting , cochrane library , abdominal pain , surgery , gastroenterology , meta analysis , antibiotics , microbiology and biotechnology , biology
What is known and Objective The purpose of this study is to explore the clinical characteristics of tigecycline‐induced acute pancreatitis. Methods We searched the PubMed/Medline, Web of Knowledge, OVID, Elsevier, Springer Link, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), Wanfang Data, and Chinese VIP databases from 2005 and identified 19 studies of tigecycline‐induced acute pancreatitis involving a total of 22 patients for inclusion in a retrospective analysis. Results and Discussion The median (range) age of 22 patients with acute pancreatitis was 58 years (range 9‐83). Overall, the median (range) time of symptom onset was 6.5 days (range 2‐28), or 6 days (range 2‐14) and 6 days (range 3‐28) in patients with or without a loading dose of tigecycline, respectively. Symptoms included nausea, vomiting and abdominal distension (73%) and abdominal pain (73%); 90% (18/20) of patients developed mild acute pancreatitis (MAP), and 10% (2/20) developed severe acute pancreatitis (SAP). Computed tomography (CT) scans showed oedematous infiltrate in 56% (10/18) of cases and acute pancreatitis in 28% (5/18) of cases. The median (range) level of lipase and amylase was 936U/L (range 382‐4089) and 588U/L (range 312‐1166), respectively. The median (range) time to recovery of symptoms was 4 days (range 1‐10), and the time for recovery of pancreatic enzymes to the normal range was 5 days (range 1‐30) after the withdrawal of tigecycline in all patients. What is new and Conclusion Clinicians should be particularly mindful of clinical signs and symptoms, the level of serum pancreatic enzymes and abdominal CT images in order to monitor the development of pancreatitis when using tigecycline.